Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arcasoy, M. O.
Right arrow Articles by Raleigh, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arcasoy, M. O.
Right arrow Articles by Raleigh, J. A.
Clinical Cancer Research Vol. 11, 20-27, January 2005
© 2005 American Association for Cancer Research

Human Cancer Biology

Erythropoietin and Erythropoietin Receptor Expression in Head and Neck Cancer: Relationship to Tumor Hypoxia

Murat O. Arcasoy1, Khalid Amin2, Shu-Chuan Chou3, Zishan A. Haroon1, Mahesh Varia3 and James A. Raleigh3

1 Department of Medicine, Duke University School of Medicine, Durham, North Carolina; 2 Biosciences Division, SRI International, Menlo Park, California; and 3 Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Requests for reprints: Murat O. Arcasoy, Divisions of Hematology and Medical Oncology, Department of Medicine, Duke University School of Medicine, DUMC Box 3912, Durham, NC 27710. Phone: 919-668-6309; Fax: 919-681-6160; E-mail: arcas001{at}mc.duke.edu


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Erythropoietin, an oxygen-regulated glycoprotein hormone, is a hematopoietic cytokine that stimulates erythropoiesis by binding to its cellular receptor [erythropoietin receptor (EPOR)]. The recombinant form of human erythropoietin is used to prevent or treat anemia in cancer patients. However, in a recent randomized, placebo-controlled trial involving patients receiving curative radiotherapy for squamous cell carcinoma of the head and neck, erythropoietin treatment was associated with poorer locoregional progression-free survival. The purpose of our study was to determine whether EPOR and its ligand erythropoietin are expressed in primary head and neck cancer. We also investigated the hypothesis that erythropoietin expression in malignant cells may be associated with the presence of tumor hypoxia, an important factor involved in resistance to radiation treatment, tumor aggressiveness, and poor prognosis.

Experimental Design: Twenty-one patients received an i.v. infusion of the hypoxia marker pimonidazole hydrochloride before multiple tumor biopsies. Contiguous sections from 74 biopsies were analyzed by immunohistochemistry for EPOR and erythropoietin expression and pimonidazole binding.

Results: EPOR expression was present in tumor cells in 97% of the biopsies. Coexpression of erythropoietin was observed in 90% of biopsies. Erythropoietin and pimonidazole adduct staining did not always colocalize within tumors, but there was a significant positive correlation between levels of microregional erythropoietin expression and pimonidazole binding.

Conclusions: The coexpression of erythropoietin and EPOR in tumor cells suggests that erythropoietin may potentially function as an autocrine or paracrine factor in head and neck cancer. The expression of the hypoxia-inducible protein erythropoietin in tumor cells correlates with levels of tumor hypoxia.

Key Words: cytokine receptor • oxygen regulation • pimonidazole • squamous cell carcinoma


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Erythropoietin, a 34-kDa glycoprotein, regulates RBC production by stimulating the proliferation, survival, and terminal differentiation of erythroid progenitor cells in the bone marrow. In contrast to other hematopoietic cytokines, erythropoietin behaves like a hormone and its physiologic production in the kidney is under the feedback control of an oxygen-sensing mechanism regulated by the binding of hypoxia-inducible factor-1 (1). The biological effects of erythropoietin are mediated by the specific binding of erythropoietin to its cognate transmembrane receptor [erythropoietin receptor (EPOR)] expressed on the surface of erythroid progenitor cells in the bone marrow (2–4) as well as several nonhematopoietic cell types, including vascular endothelial cells (5), cardiac myocytes (6), neurons (7, 8), and macrophages (9). Distinct from its regulatory function in erythropoiesis, erythropoietin exhibits diverse nonhematopoietic biological activities, such as the protection against anoxic injury in the brain (10) and cardiovascular system (6, 11) and the stimulation of physiologic angiogenesis in the female reproductive tract (12) and during wound healing (9).

The recombinant form of human erythropoietin (rHuEPO) has been widely used in clinical practice for the prevention or treatment of anemia associated with cancer and chemoradiation therapy (13). The benefits and safety of rHuEPO in anemic cancer patients leading to increased hemoglobin levels, decreased RBC transfusions, and improved quality of life have been documented in several large studies (14–16) as well as in a randomized, placebo-controlled study that showed a trend in overall survival favoring rHuEPO (17). In patients with head and neck cancer receiving chemotherapy, rHuEPO improved hemoglobin levels and reduced transfusion requirements (18–20). Previous studies have explored the incorporation of rHuEPO in curative treatment regimens to improve outcome of head and neck cancer patients. Aretrospective clinical study found that rHuEPO administration during neoadjuvant chemoradiotherapy may improve tumor control and survival (21), consistent with the findings of several preclinical studies where erythropoietin was shown to modulate tumor hypoxia and increase radiation sensitivity in various animal models of human cancer (22–24). However, a recent double-blind, randomized, placebo-controlled multicenter trial found poorer locoregional progression-free survival in rHuEPO-treated patients with head and neck cancer compared with placebo despite correction of anemia (25). The latter prospective study was specifically designed to investigate the effect of rHuEPO on outcome for patients with head and neck cancer treated with radiotherapy only. It was noted, however, that the adverse outcomes may be associated with the study design that allowed higher than recommended increases in hemoglobin in erythropoietin-treated patients (26). It was also speculated that underlying biological factors, such as potential direct effects of erythropoietin on tumors, may underlie the unexpected, unfavorable clinical results observed in the erythropoietin arm (25).

A series of recent studies from our laboratories and others have reported EPOR expression in various types of malignant human tumors and continuous cancer cell lines, including breast cancer (27–30), melanoma (31), renal cell carcinoma (32), gastric cancer (33), pediatric tumors (34), and uterine and ovarian carcinomas (35). In breast cancer cells and squamous cell carcinomas of the uterine cervix, coexpression of EPOR and its ligand erythropoietin was detected in primary tumors, suggesting that erythropoietin-EPOR may potentially play a role as an autocrine or paracrine growth factor in some malignancies (29, 36). In our studies of erythropoietin-EPOR expression and its biology in human cancer, we explored the expression of erythropoietin and EPOR protein in squamous cell carcinomas of the head and neck using immunohistochemistry. Furthermore, we tested the hypothesis that the expression of erythropoietin, an oxygen-regulated protein, in malignant head and neck tumors may be associated with the presence of tumor hypoxia, a factor that is associated with tumor aggressiveness, treatment resistance, and poor prognosis insquamous cell carcinomas of the head and neck (37–40).


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients. Twenty-one patients with squamous cell carcinoma of the head and neck were enrolled in a tumor hypoxia study in accordance with a research protocol approved by the Institutional Review Board at the University of North Carolina Hospitals. All patients provided signed informed consent before their participation in the study. The primary tumors were localized to the larynx in nine patients, oropharynx in six patients (four base of tongue and two tonsillar region), oral cavity in five patients (three floor of mouth, one tongue, and one alveolar ridge), and hypopharynx in one patient. The tissue specimen from a patient with laryngeal cancer was excluded from the studies because of the availability of only a single, small, and fragmented biopsy. Two or more biopsy specimens were available from the tumors of the remaining 20 patients, and 74 biopsies in total were analyzed in the studies. The site, stage, and grade of each patient's tumor and the baseline hemoglobin and hematocrit values are illustrated in Table 1, and the number of biopsies obtained from each tumor are illustrated in Table 2.


View this table:
[in this window]
[in a new window]
  		Table 1 Clinical characteristics and mean weighed staining intensity scores for EPOR and erythropoietin expression in squamous cell carcinomas of the head and neck

 

View this table:
[in this window]
[in a new window]
  		Table 2 Pimonidazole binding and erythropoietin expression in head and neck carcinomas

 
Labeling of Tumor Hypoxia. The hypoxia marker pimonidazole hydrochloride (Hypoxyprobe-1) was obtained from NPI, Inc. (Belmont, MA). Before tumor biopsy, the patients received pimonidazole hydrochloride (0.5 g/m2) diluted in100mL of 0.9% NaCl infused i.v. >20 minutes. Between 16 to 24 hours later, multiple incisional biopsies were obtained from the primary tumors. After the biopsies, the fresh tumor samples were placed in cold 10% neutral-buffered formalin held at 4°C for 12 to 24 hours and processed into paraffin blocks. Four-µm-thick contiguous sections were cut and mounted on glass slides before immunohistochemical staining. One slide per block was stained with H&E for pathologic review to confirm the presence of tumor.

Immunohistochemical Staining. Immunostaining for erythropoietin and EPOR was carried out on contiguous sections using procedures described previously with some modifications (29). The primary antibodies were monoclonal anti-erythropoietin (mAb-287, 1:25 dilution) from R&D Systems (Minneapolis, MN) and polyclonal anti-EPOR (C-20, 1:50 dilution) from Santa Cruz Biotechnology (Santa Cruz, CA). EPOR expression was confirmed using a second monoclonal anti-EPOR (mh2er 16.5.1, 1:50 dilution) generously provided by Genetics Institute (Cambridge, MA). Negative controls from which primary antibodies were omitted from the staining procedure were free of nonspecific background staining. The sections were deparaffinized in Hemo-D, rehydrated in graded alcohols, and subjected to endogenous peroxidase block in 3% H2O2. For EPOR immunostaining, antigen retrieval was carried out by boiling the sections in antigen retrieval solution (Innovex Biosciences, Richmond, CA), whereas sections for erythropoietin immunostaining were boiled in 10% citrate buffer for antigen retrieval. This was followed by blocking with 5% donkey serum (Jackson Immunoresearch Labs, West Grove, PA). Slides were incubated with anti-erythropoietin or anti-EPOR antibodies overnight at 4°C and then washed and incubated with either biotinylated donkey anti-mouse (1:1,000) or anti-rabbit (1:2,000) secondary antibodies (Jackson Immunoresearch Labs) at 37°C for 25 minutes followed by another incubation for 25 minutes with avidin-biotin peroxidase complex (ABC Kit, Vector Laboratories, Burlingame, CA). Finally, the sections were developed with diaminobenzidine tetrahydrochloride chromogen and counterstained with hematoxylin. Sections contiguous to those stained for erythropoietin and EPOR were stained for pimonidazole binding using a mouse monoclonal antibody against pimonidazole adducts (clone 4.3.11.3, 70 µg/mL, IgG1, diluted 1:50) as described in detail previously (41).

Semiquantitative Analysis of Erythropoietin, EPOR Staining, and Tumor Hypoxia. Immunohistochemistry results were evaluated by two pathologists (K.A. and Z.A.H.) in a blinded fashion, and differences between the two investigators were resolved by consensus. Cytoplasmic or membrane staining for erythropoietin and EPOR were considered positive. Immunohistochemical detection of tumor hypoxia using immunostaining for pimonidazole binding has been described previously (42–44). To assess the percentage of tumor cells staining for erythropoietin, EPOR, or pimonidazole adducts, the entire tumor section (regardless of the number of fields) was examined at low magnification (x25-50) without taking into account areas of acellularity, necrosis, and stroma. For assessment of erythropoietin and EPOR expression, we also evaluated the intensity of thestaining in tumor cells. The percentage of tumor cells that exhibited no erythropoietin or EPOR staining (intensity score =0) or weak (score = 1), moderate (score = 2), or intense (score = 3) staining was determined by microscopic examination at higher magnification (x100-200). The semiquantitative immunoreactivity score was derived from the product of the percentage of tumor cells staining for erythropoietin or EPOR and the intensity score of that staining using the formula: Weighed staining intensity = {sum} Intensity score x Percentage of cells. The maximum weighed staining intensity score was 300, and the expression data was presented as means ± SE, except for tumors 1, 2 and 5, which had only two biopsies available. The intensity of pimonidazole binding was not factored as discussed previously (44). Although the extent of 2-nitroimidazole immunostaining measures the extent of oxygen tensions ≤10 mm Hg, the intensity of immunostaining is affected by pharmacokinetic and pharmacodynamic factors besides hypoxia. Microregional comparison of erythropoietin expression and tumor hypoxia in tumor fields was carried out at higher magnification (x100-200) for each biopsy on a section-by-section basis to assess individual microscopic fields with respect to (a) overlap, (b) no overlap, and (c) a mix of overlap and no overlap with pimonidazole immunostaining (44).

Statistical Analyses. The analyses were done using GraphPad Prism version 3.0 for Windows software. The relationships among tumor hypoxia, erythropoietin-EPOR expression,and other variables were examined by two-tailed Spearman's rank correlation analysis and when appropriate using Kruskal-Wallis ANOVA and Dunn multiple comparisons post hoc test. P < 0.05 was considered significant.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of EPOR and Erythropoietin in Squamous Cell Carcinomas of the Head and Neck. To determine whether primary squamous cell carcinomas of the head and neck express EPOR and its ligand erythropoietin, we carried out immunohistochemical analysis on a total of 74 tumor biopsies from 20 patients. Photomicrographs in Fig. 1 are representative of the immunostaining patterns for EPOR (A, B, and C) and erythropoietin (D). EPOR was expressed in tumor cells in 72 of 74 (97%) biopsies and exhibited predominantly a cytoplasmic pattern of immunostaining (Fig. 1A and B). EPOR expression was also observed in vascular endothelial cells (Fig. 1B). EPOR immunoreactivity localized to the membrane of tumor cells in some sections (Fig. 1C). The pattern and high frequency of EPOR staining is comparable with what our laboratory and others have observed in other types of neoplasms that express EPOR such as breast cancer and squamous cell carcinomas of the uterine cervix (27–29, 36). Erythropoietin expression in tumor cells was observed in 67 of 74 (90%) biopsies and exhibited focal immunoreactivity of varying intensity in many tumors (Figs. 1D and 2). We found coexpression of EPOR and its ligand erythropoietin in most (90%) of biopsies with overlap of immunoreactivity in many cases. The results of immunohistochemistry analysis for EPOR and erythropoietin expression are summarized in Table 1. There was no significant difference in erythropoietin or EPOR expression scores between different primary tumor sites (P > 0.2, Kruskal-Wallis test). There was no correlation between baseline hemoglobin or hematocrit levels and tumor erythropoietin (P > 0.2) or EPOR expression scores (P > 0.7, Spearman rank correlation).



View larger version (68K):
[in this window]
[in a new window]
  		Fig. 1 Immunostaining for EPOR and erythropoietin expression in biopsies from squamous cell carcinomas of the head and neck. A, EPOR immunoreactivity in cytoplasm of tumor cells. Magnification, x200. B, EPOR staining in tumor cells and vascular endothelial cells (arrows). C and D, membrane EPOR immunoreactivity (C) and erythropoietin expression (D) in tumor cells in contiguous sections. Magnification in B-D, x400.

 


View larger version (96K):
[in this window]
[in a new window]
  		Fig. 2 Photomicrographs of serial sections of tumor biopsies immunostained for erythropoietin and pimonidazole adducts. Five representative tumor biopsies stained for erythropoietin (EPO; A, C, E, G, and I) and pimonidazole binding (Pimo-hypoxia; B, D, F, H, and J). A-D, overlap of erythropoietin staining and pimonidazole binding. E-F, mixed pattern of overlap and no overlap of erythropoietin staining and pimonidazole binding. G-H, erythropoietin immunoreactivity in the absence of pimonidazole binding. I-J, staining for pimonidazole adducts in the absence of erythropoietin staining. Magnification, x200 (A-F) and x100 (G-J).

 
Detection of Tumor Hypoxia by Pimonidazole Binding. Qualitative assessment of tumor hypoxia detected by pimonidazole binding revealed the presence of tumor hypoxia in 17 of 20 patients with head and neck carcinoma, with immunostaining for pimonidazole adducts observed in 63 of 74 (85%) total tumor biopsy sections. Representative photomicrographs illustrating pimonidazole immunostaining of hypoxic tumor cells are illustrated in Fig. 2B, D, F, H, and J. Semiquantitative assessment of the percentage tumor area labeled for hypoxia based on immunoreactivity for pimonidazole binding was carried out for each biopsy section and the mean fraction of tumor area was determined for each tumor (Table 2). In hypoxic tumors, the mean area fractions labeled with pimonidazole exhibited a wide range from 0.7% to 29% of the total tumor area. These results are consistent with the findings of previous studies evaluating tumor hypoxia in squamous cell carcinomas (40, 43–46). In this cohort of patients, there was no correlation between tumor hypoxia and baseline hemoglobin or hematocrit levels (P > 0.9 and P > 0.2, respectively, Spearman rank correlation). There was no significant difference in hypoxia status between different primary tumor sites (P > 0.9; Kruskal-Wallis test).

Relationship between Erythropoietin Expression and Pimonidazole Binding. The physiologic expression of erythropoietin in the kidneys is under the control of an oxygen-sensing mechanism. To test the hypothesis that in vivo tumor hypoxia and erythropoietin expression may be coupled in squamous carcinoma cells, we compared the microregional pattern and the extent of erythropoietin expression and hypoxia in tumor biopsies using contiguous tissue sections. In 4 of 74 biopsies, neither erythropoietin expression nor pimonidazole binding was present. Figure 2 illustrates representative immunostaining patterns for erythropoietin (A, C, E, G, and I) and pimonidazole adducts (B, D, F, H, and J) in contiguous sections. Figure 2A and C shows two tumors exhibiting erythropoietin immunoreactivity overlapping with regions of pimonidazole binding in the contiguous sections in Fig. 2B and D, respectively. Although this pattern of pimonidazole and erythropoietin overlap suggests that erythropoietin may serve as an endogenous hypoxia marker, the overlap pattern was observed in only 19% (13 of 70) of the biopsies. The most common pattern of hypoxia and erythropoietin expression was observed in 36 (51%) biopsies in which a mixture of overlap and no overlap of erythropoietin and hypoxia occurred in the same biopsy (Table 2). An example of this pattern is illustrated in Fig. 2E and F in which an area of overlap for erythropoietin staining and pimonidazole binding is adjacent to a hypoxic tumor zone with pimonidazole binding that does not exhibit erythropoietin immunoreactivity. A third pattern of erythropoietin expression and pimonidazole binding was characterized by staining for pimonidazole adducts in tumor zones different from those for erythropoietin staining, observed in 21 of 70 (30%) biopsies. In 6 of these biopsy sections, lack of overlap was attributable to expression of erythropoietin in the absence of pimonidazole binding (Fig. 2, compare G and H). In 2 biopsy sections, the lack of overlap was due to presence of tumor hypoxia and the absence of erythropoietin expression (Fig. 2, compare I and J). In the remaining 13 biopsies, both erythropoietin staining and pimonidazole binding were observed but without any regions of overlap.

Quantitative comparisons between microregional erythropoietin expression and tumor hypoxia were done initially on a tumor-by-tumor basis (Fig. 3). The percentage fraction of tumor area staining positive for erythropoietin protein and pimonidazole binding was assessed for each biopsy section and the mean values for each tumor were calculated (Table 2). The data were organized in ascending order of tumor hypoxia. Hypoxia was present in all but three tumors. Areas immunostained for erythropoietin were measurable in all tumors with a wide range from 1.5% to 86%. On a tumor-by-tumor basis, there was a significant positive correlation between erythropoietin expression and pimonidazole binding as shown in Fig. 4A (P < 0.001). Figure 4B illustrates the results of the analysis on a biopsy-by-biopsy basis, demonstrating that the correlation between erythropoietin expression and hypoxia was weaker but remained significant (P < 0.002). In contrast to the correlation between pimonidazole binding and erythropoietin, there was no correlation between pimonidazole binding and EPOR expression (P > 0.2, Spearman rank correlation). We also compared the levels of pimonidazole binding to the mean weighed staining intensity erythropoietin score that was determined for each tumor. The weighed staining intensity score (Table 1) takes into account notonly the percentage of tumor cells that exhibit staining but also the intensity of erythropoietin staining in the tumor cells. There was a significant positive correlation between pimonidazole binding and the erythropoietin expression score (r = 0.678, P < 0.002, Spearman rank correlation). Figure 4C illustrates the results of comparisons of the extent of pimonidazole binding in tumor biopsies stratified into absent, low, moderate, or high erythropoietin expression groups according to the erythropoietin expression scores. Tumor biopsies with moderate or high erythropoietin scores showed significantly higher pimonidazole binding compared with tumors with low erythropoietin scores or no erythropoietin expression (P < 0.01).



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3 Microregional erythropoietin expression and pimonidazole labeling in hypoxic tumors. Percentage fraction of tumor area staining positive for erythropoietin (gray columns) and pimonidazole binding (black columns) was determined for all biopsy sections as described in MATERIALS AND METHODS. Columns, mean for each tumor; bars, SE. Data are organized in order of increasing hypoxia from left to right. Bars are absent for tumors 1, 2, and 5 where fewer than three biopsies were available. Tumor numbers refer to the tumors described in Tables 1 and 2.

 


View larger version (11K):
[in this window]
[in a new window]
  		Fig. 4 Comparisons between erythropoietin protein expression and pimonidazole binding. A, percentage fraction of tumor area staining for erythropoietin (% EPO) and pimonidazole binding (% pimonidazole) was determined for all biopsy sections as described in MATERIALS AND METHODS. A significant correlation was observed between levels of erythropoietin and pimonidazole labeling on a tumor-by-tumor basis using mean expression levels for each tumor (r = 0.736, P < 0.001, Spearman rank correlation). B, comparison of percentage fraction tumor area staining for erythropoietin and pimonidazole binding on a biopsy-by-biopsy basis (r = 0.365, P < 0.002, Spearman rank correlation). C, comparison between pimonidazole binding and weighed mean erythropoietin expression score. Tumor biopsies were stratified according to their erythropoietin scores into absent (0), low (1-20), moderate (21-40), or high (>40) erythropoietin expression groups. Bars, median values of pimonidazole binding in each group. Tumors with moderate or high erythropoietin scores showed significantly higher pimonidazole binding compared with tumors with absent or low erythropoietin scores (*, P < 0.01, Kruskal-Wallis and Dunn multiple comparisons post hoc test).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we show the expression of EPOR in primary squamous cell carcinomas of the head and neck. EPOR expression in tumor cells is consistent with the possibility that rHuEPO may exert direct effects in the malignant cells that may modulate cellular proliferation, apoptosis, or responsiveness to chemoradiation therapy (25). However, further studies using both in vitro and in vivo experimental models are required to characterize the direct effects, if any, of exogenous erythropoietin in tumor cells that express EPOR. The biology of erythropoietin-EPOR in squamous cell carcinomas of the head and neck is likely to be complex in view of our findings that tumor cells express not only EPOR but also endogenous erythropoietin protein. Furthermore, EPOR expression is not restricted to tumor cells, as it is also expressed in vascular endothelial cells and tumor vasculature (5, 12, 35, 47–49). EPOR expression in vascular endothelial cells is associated with the ability of erythropoietin to stimulate physiologic in vivo angiogenesis in the female genital tract (12), chick embryo chorioallantoic membrane (49), and during wound healing (9). It remains to be determined whether erythropoietin-EPOR signaling may directly modulate pathologic tumor angiogenesis, a process that is essential for tumor formation and progression.

We found expression of erythropoietin protein in the majority of primary head and neck cancers and investigated the hypothesis that erythropoietin expression in tumor cells may be associated with the presence of hypoxia, an indicator of poor outcome in some types of cancer (50). In patients with head and neck cancer, tumor hypoxia has been associated with aggressive course and resistance to radiation therapy (37–39) and high levels of pimonidazole binding in hypoxic tumors have been associated with poor locoregional control (40). Hypoxia-inducible erythropoietin expression has been reported in nonrenal sites, including brain astrocytes (51), and the female genital tract where erythropoietin expression was also inducible by estrogen (12, 52). Our studies addressed the question of whether erythropoietin may serve as an endogenous hypoxia marker in head and neck tumors. We found that erythropoietin expression did not always colocalize with regional tumor hypoxia as determined by pimonidazole binding. However, there was a significant positive correlation between levels of erythropoietin expression and tumor hypoxia as determined by pimonidazole binding.

The findings of previous preclinical studies of erythropoietin-EPOR biology in cancer support the possibility that expression of erythropoietin and EPOR in squamous cell carcinomas of the head and neck is likely to be functionally significant. For instance, rHuEPO treatment of monolayer cultures of uterine cervix squamous carcinoma cells was associated with diminished cytotoxic effect and apoptosis induced by the chemotherapeutic agent cisplatin in vitro (36). In animal studies using xenografts of human female genital tract cancers, gastric choriocarcinomas or melanoma, it was shown that administration of inhibitors of erythropoietin-EPOR signaling resulted in significant antitumor effects, characterized by the destruction of xenografts as well as tumor vasculature (35, 53). In studies in our laboratory using a syngeneic breast cancer model, administration of erythropoietin-EPOR inhibitors resulted in significant tumor growth delay (29). Thus, a growing body of preclinical experimental evidence suggests that functional erythropoietin-EPOR signaling may represent an emerging therapeutic target in several different types of cancer.

A recent randomized study involving patients with locally advanced head and neck cancer treated with concomitant chemoradiotherapy did not find a significant effect of rHuEPO on progression-free or overall survival (20). Thus, further studies are required to determine whether EPOR expression in malignant head and neck tumors may have contributed to the reported unfavorable effect of systemic rHuEPO on treatment response and outcome in patients treated with radiation therapy alone (25). Irrespective of potential direct effects, if any, of exogenous rHuEPO in tumor cells, the coexpression of EPOR and its ligand erythropoietin in squamous cell carcinomas of the head and neck suggests that endogenous erythropoietin may play a role as a potential autocrine or paracrine growth factor in cancer cells. The expression of EPOR in tumor cells needs to be taken into consideration in the design of future clinical trials investigating the role of rHuEPO in head and neck cancer. Further preclinical studies investigating the biology of erythropoietin-EPOR signaling in squamous cell carcinoma of the head and neck are warranted.


   ACKNOWLEDGMENTS
 
We thank Lisa Licht, R.N., for assistance with patient recruitment.


   FOOTNOTES
 
Grant support: NIH, National Institute of Diabetes and Digestive and Kidney Diseases grant DK02566 (M.O. Arcasoy) and National Cancer Institute grants CA85361, CA68826, and RR00046 (J.A. Raleigh and M. Varia).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/13/04; revised 9/16/04; accepted 10/ 6/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864–77.[Free Full Text]
  2. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989;57:277–85.[CrossRef][Medline]
  3. Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 1990;76:31–5.[Abstract/Free Full Text]
  4. Winkelmann JC, Penny LA, Deaven LL, Forget BG, Jenkins RB. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood 1990;76:24–30.[Abstract/Free Full Text]
  5. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;91:3974–8.[Abstract/Free Full Text]
  6. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18:1031–3.[Abstract/Free Full Text]
  7. Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208–16.[Abstract/Free Full Text]
  8. Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A 1995;92:3717–20.[Abstract/Free Full Text]
  9. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 2003;163:993–1000.[Abstract/Free Full Text]
  10. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998;95:4635–40.[Abstract/Free Full Text]
  11. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973–9.[Abstract/Free Full Text]
  12. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381–7.[Abstract/Free Full Text]
  13. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303–20.[Abstract/Free Full Text]
  14. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218–34.[Abstract/Free Full Text]
  15. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412–25.[Abstract]
  16. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality oflife are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82.[Abstract/Free Full Text]
  17. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74.[Abstract/Free Full Text]
  18. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997;79:1623–8.[CrossRef][Medline]
  19. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer 1999;86:1362–7.[CrossRef][Medline]
  20. Rosen FR, Haraf DJ, Kies MS, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689–97.[Abstract/Free Full Text]
  21. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705–15.[CrossRef][Medline]
  22. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752–6.[Medline]
  23. Stuben G, Pottgen C, Knuhmann K, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358–62.[CrossRef][Medline]
  24. Pinel S, Barberi-Heyob M, Cohen-Jonathan E, et al. Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys 2004;59:250–9.[CrossRef][Medline]
  25. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head andneck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.[CrossRef][Medline]
  26. Leyland-Jones B, Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80.
  27. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561–5.[Abstract/Free Full Text]
  28. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95:969–81.[CrossRef][Medline]
  29. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911–8.[Medline]
  30. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307:999–1007.[CrossRef][Medline]
  31. Selzer E, Wacheck V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421–6.[CrossRef][Medline]
  32. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647–57.[CrossRef][Medline]
  33. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 2003;42:246–50.[CrossRef][Medline]
  34. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477–87.[CrossRef][Medline]
  35. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001;84:836–43.[CrossRef][Medline]
  36. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789–806.[Abstract/Free Full Text]
  37. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831–8.[Medline]
  38. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.[Medline]
  39. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285–9.[CrossRef][Medline]
  40. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066–74.[Abstract/Free Full Text]
  41. Chou SC, Azuma Y, Varia MA, Raleigh JA. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 2004;90:728–35.[CrossRef][Medline]
  42. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 2001;49:569–74.[CrossRef][Medline]
  43. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998;58:3765–8.[Abstract/Free Full Text]
  44. Raleigh JA, Chou SC, Calkins-Adams DP, Ballenger CA, Novotny DB, Varia MA. A clinical study of hypoxia and metallothionein proteinexpression in squamous cell carcinomas. Clin Cancer Res 2000;6:855–62.[Abstract/Free Full Text]
  45. Wijffels KI, Kaanders JH, Rijken PF, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. BrJCancer 2000;83:674–83.
  46. Azuma Y, Chou SC, Lininger RA, Murphy BJ, Varia MA, Raleigh JA. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin. Clin Cancer Res 2003;9:4944–52.[Abstract/Free Full Text]
  47. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990;87:5978–82.[Abstract/Free Full Text]
  48. Yamaji R, Okada T, Moriya M, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996;239:494–500.[Medline]
  49. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627–36.[Abstract/Free Full Text]
  50. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–76.[Abstract/Free Full Text]
  51. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994;269:19488–93.[Abstract/Free Full Text]
  52. Masuda S, Kobayashi T, Chikuma M, Nagao M, Sasaki R. The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner. Am J Physiol Endocrinol Metab 2000;278:E1038–44.[Abstract/Free Full Text]
  53. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021–9.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. N. Hamadmad and R. J. Hohl
Erythropoietin Stimulates Cancer Cell Migration and Activates RhoA Protein through a Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase-Dependent Mechanism
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1227 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Saintigny, B. Besse, P. Callard, A.-C. Vergnaud, S. Czernichow, M. Colombat, P. Girard, P. Validire, J.-L. Breau, J.-F. Bernaudin, et al.
Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non Small Cell Lung Cancer
Clin. Cancer Res., August 15, 2007; 13(16): 4825 - 4831.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Kokhaei, A. O. Abdalla, L. Hansson, E. Mikaelsson, M. Kubbies, A. Haselbeck, H. Jernberg-Wiklund, H. Mellstedt, and A. Osterborg
Expression of Erythropoietin Receptor and In vitro Functional Effects of Epoetins in B-Cell Malignancies
Clin. Cancer Res., June 15, 2007; 13(12): 3536 - 3544.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Zeuner, M. Signore, D. Martinetti, M. Bartucci, C. Peschle, and R. De Maria
Chemotherapy-Induced Thrombocytopenia Derives from the Selective Death of Megakaryocyte Progenitors and Can Be Rescued by Stem Cell Factor
Cancer Res., May 15, 2007; 67(10): 4767 - 4773.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
W. M. Brown, P. Maxwell, A. N.J. Graham, A. Yakkundi, E. A. Dunlop, Z. Shi, P. G. Johnston, and T. R.J. Lappin
Erythropoietin Receptor Expression in Non-Small Cell Lung Carcinoma: A Question of Antibody Specificity
Stem Cells, March 1, 2007; 25(3): 718 - 722.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Leo, L.-C. Horn, C. Rauscher, B. Hentschel, A. Liebmann, G. Hildebrandt, and M. Hockel
Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis
Clin. Cancer Res., December 1, 2006; 12(23): 6894 - 6900.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Henke, D. Mattern, M. Pepe, C. Bezay, C. Weissenberger, M. Werner, and F. Pajonk
Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?
J. Clin. Oncol., October 10, 2006; 24(29): 4708 - 4713.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Henke, A. Verma, G. Acs, S. Elliott, L. Busse, C. Spahr, and A. M. Sinclair
Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate
Blood, August 1, 2006; 108(3): 1107 - 1109.
[Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. R. Laderoute, K. Amin, J. M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz, and B. Viollet
5'-AMP-Activated Protein Kinase (AMPK) Is Induced by Low-Oxygen and Glucose Deprivation Conditions Found in Solid-Tumor Microenvironments.
Mol. Cell. Biol., July 1, 2006; 26(14): 5336 - 5347.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, et al.
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
J Natl Cancer Inst, May 17, 2006; 98(10): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Elliott, L. Busse, M. B. Bass, H. Lu, I. Sarosi, A. M. Sinclair, C. Spahr, M. Um, G. Van, and C. G. Begley
Anti-Epo receptor antibodies do not predict Epo receptor expression
Blood, March 1, 2006; 107(5): 1892 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell
Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst
Erythropoietin Biology in Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. M. Erovic, M. Pelzmann, M. Ch. Grasl, J. Pammer, G. Kornek, W. Brannath, E. Selzer, and D. Thurnher
Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3{sigma} Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Clin. Cancer Res., December 15, 2005; 11(24): 8632 - 8636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. C. Winter, K. A. Shah, L. Campo, H. Turley, R. Leek, R. J. Corbridge, G. J. Cox, and A. L. Harris
Relation of Erythropoietin and Erythropoietin Receptor Expression to Hypoxia and Anemia in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., November 1, 2005; 11(21): 7614 - 7620.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. Maiese, F. Li, and Z. Z. Chong
Erythropoietin and Cancer--Reply
JAMA, April 20, 2005; 293(15): 1858 - 1859.
[Full Text] [PDF]

<
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar